A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT ID: NCT00420992

Last Updated: 2013-09-20

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

547 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to evaluate the efficacy of ALO-01 compared with placebo for the treatment of chronic moderate to severe pain (focusing on osteoarthritis of the hip or knee) as measured by mean change in diary Brief Pain Inventory (BPI) score of average pain (daily scores of average pain averaged over 7 days) from randomization to 12 weeks following randomization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis Chronic Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

hip knee pain osteoarthritis OA Kadian Alpharma naltrexone Opioid morphine Embeda ALO-01

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALO-01

Up to 80 mg twice a day (bid)

Group Type EXPERIMENTAL

ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)

Intervention Type DRUG

capsules, up to 80 mg bid

Placebo

Twice a day (bid)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

capsules, bid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)

capsules, up to 80 mg bid

Intervention Type DRUG

Placebo

capsules, bid

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Embeda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is 21 years of age or older
* Subject is either not of childbearing potential OR subject must use an acceptable method of birth control if of childbearing potential
* Negative pregnancy test if female of childbearing potential
* Subject is in general good health
* Subject required treatment of joint pain within the last 90 days
* Subject has primary diagnosis of osteoarthritis (OA) of the hip or knee

Exclusion Criteria

* Subject has a documented history of allergic reaction or intolerance to morphine or other opioids
* Subject is pregnant or breast-feeding
* Subject is receiving systemic chemotherapy
* Subject has a history of drug abuse/dependence/misuse or alcohol abuse/dependence
* Subject has history of major depressive disorder not controlled with medication
* Subject has any chronic pain syndrome (i.e., fibromyalgia) that may interfere with the symptoms of OA
* Subject has active gastrointestinal disease, with the exception of gastroesophageal reflux disease (GERD)
* Subject has a documented history of rheumatoid arthritis, uncontrolled inflammatory arthritis or non-steroidal anti-inflammatory drug (NSAID)-dependent inflammatory arthritis
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James B. Jones, MD, PharmD

Role: STUDY_DIRECTOR

Alpharma Pharmceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Birmingham Pain Center

Birmingham, Alabama, United States

Site Status

Horizon Research Group

Mobile, Alabama, United States

Site Status

Arizona Center for Clinical Research

Peoria, Arizona, United States

Site Status

Arizona Research Center, Inc

Phoenix, Arizona, United States

Site Status

Premiere Pharmaceutical Research, LLC

Tempe, Arizona, United States

Site Status

Advanced Clinical Research Institute

Anaheim, California, United States

Site Status

Orange County Clinical Trials

Anaheim, California, United States

Site Status

STAT-CARE / Crest Clinical Trials

Anaheim, California, United States

Site Status

Southbay Pharma Research

Buena Park, California, United States

Site Status

Providence Clinical Res. (C-trials)

Burbank, California, United States

Site Status

Med Investigators Inc

Fair Oaks, California, United States

Site Status

Quality of Life Medical Center, LLC

Hawaiian Gardens, California, United States

Site Status

NervePro Research

Irvine, California, United States

Site Status

UCSD Pain and Palliative Care

La Jolla, California, United States

Site Status

USCD Pain and Palliative Care

La Jolla, California, United States

Site Status

Private Practice

Pico Rivera, California, United States

Site Status

Pain Institute of Santa Monica

Santa Monica, California, United States

Site Status

Boling Clinical Trials

Upland, California, United States

Site Status

Mountain View Clinical Research, Inc

Denver, Colorado, United States

Site Status

Stamford Therapeutics Consortium

Stamford, Connecticut, United States

Site Status

New England Research Associates, LLC

Trumbull, Connecticut, United States

Site Status

MD Clinical

Hallandale, Florida, United States

Site Status

Eastern Research

Hialeah, Florida, United States

Site Status

Florida Institute of Medical Research

Jacksonville, Florida, United States

Site Status

Drug Study Institiute

Jupiter, Florida, United States

Site Status

FPA Clinical Research

Kissimmee, Florida, United States

Site Status

Innovative Research of West Florida

Largo, Florida, United States

Site Status

Pharmaceutical Research Associates Inc

Merritt Island, Florida, United States

Site Status

Ormond Medical Arts - Pharmaceutical Research Center

Ormond Beach, Florida, United States

Site Status

University Clinical Research, Inc

Pembroke Pines, Florida, United States

Site Status

Coastal Medical Research

Port Orange, Florida, United States

Site Status

Stedman Clinical Trials

Tampa, Florida, United States

Site Status

Gold Coast Research LLC

Weston, Florida, United States

Site Status

River Birch Research Alliance

Blue Ridge, Georgia, United States

Site Status

Best Clinical Research

Decatur, Georgia, United States

Site Status

Non-Surgical Orthopaedic and Spine Center

Marietta, Georgia, United States

Site Status

Drug Studies America

Marietta, Georgia, United States

Site Status

Northwest Clinical Trials

Boise, Idaho, United States

Site Status

Research Associates of Central Illinois

Peoria, Illinois, United States

Site Status

MediSphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Welborn Clinic

Newburgh, Indiana, United States

Site Status

International Clinical Research Institute, Inc

Overland Park, Kansas, United States

Site Status

Clinical Trials Management, LLC

Mandeville, Louisiana, United States

Site Status

Lousiana Research Associates Inc.

New Orleans, Louisiana, United States

Site Status

Internal Research Center

Towson, Maryland, United States

Site Status

Phase III Clinical Research

Fall River, Massachusetts, United States

Site Status

Northeast Medical Research Associates, Inc

No Dartmouth, Massachusetts, United States

Site Status

FutureCare Studies

Springfield, Massachusetts, United States

Site Status

Synergy Medical Education Alliance

Saginaw, Michigan, United States

Site Status

Medex Healthcare Research Inc

St Louis, Missouri, United States

Site Status

Lovelace Scientific

Henderson, Nevada, United States

Site Status

Advanced Biomedical Research of America

Las Vegas, Nevada, United States

Site Status

Partners in Primary Care

Voorhees Township, New Jersey, United States

Site Status

Elkind Headache Center

Mount Vernon, New York, United States

Site Status

The Arthritis Clinic and Carolina Bone and Joint

Charlotte, North Carolina, United States

Site Status

The Center for Clinical Research, LLC

Winston-Salem, North Carolina, United States

Site Status

Community Research

Cincinnati, Ohio, United States

Site Status

Community Research

Cincinnati, Ohio, United States

Site Status

Clinical Research Source, Inc

Toledo, Ohio, United States

Site Status

COR Clinical Research

Oklahoma City, Oklahoma, United States

Site Status

Health Research Institute

Oklahoma City, Oklahoma, United States

Site Status

Cutting Edge Research

Oklahoma City, Oklahoma, United States

Site Status

Tulsa Clinical Research

Tulsa, Oklahoma, United States

Site Status

LVH Neurosciences and Pain Research

Allentown, Pennsylvania, United States

Site Status

Pennsylvania Research Institute

Bensalem, Pennsylvania, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Commonwealth Primary Care / Fleetwood Clinical Research

Fleetwood, Pennsylvania, United States

Site Status

Pivotal Clinical Research, LLC

Souderton, Pennsylvania, United States

Site Status

Tipton Medical and Diagnostic Center

Tipton, Pennsylvania, United States

Site Status

Premier Medical Group

Clarksville, Tennessee, United States

Site Status

SCRI

Cordova, Tennessee, United States

Site Status

Comprehensive Pain Specialists

Hendersonville, Tennessee, United States

Site Status

SCRI

Memphis, Tennessee, United States

Site Status

Integrity Clinical Research, LLC

Milan, Tennessee, United States

Site Status

Walter F. Chase, MD, PA

Austin, Texas, United States

Site Status

InSite Clinical Research

DeSoto, Texas, United States

Site Status

Team Research of Central Texas

Killeen, Texas, United States

Site Status

Radiant Research, San Antonio Northeast

San Antonio, Texas, United States

Site Status

North San Antonio Healthcare Associates

San Antonio, Texas, United States

Site Status

Progressive Clinical Research

San Antonio, Texas, United States

Site Status

HypotheTest, LLC

Roanoke, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Setnik B, Pixton GC, Webster LR. Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials. Curr Med Res Opin. 2016;32(3):563-72. doi: 10.1185/03007995.2015.1131153. Epub 2016 Jan 26.

Reference Type DERIVED
PMID: 26695349 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ALO-KNT-301

Identifier Type: -

Identifier Source: org_study_id